[go: up one dir, main page]

AR080892A2 - Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo - Google Patents

Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo

Info

Publication number
AR080892A2
AR080892A2 ARP110101253A ARP110101253A AR080892A2 AR 080892 A2 AR080892 A2 AR 080892A2 AR P110101253 A ARP110101253 A AR P110101253A AR P110101253 A ARP110101253 A AR P110101253A AR 080892 A2 AR080892 A2 AR 080892A2
Authority
AR
Argentina
Prior art keywords
complex
water insoluble
prepare
acetate
phthalate
Prior art date
Application number
ARP110101253A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080892(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR080892A2 publication Critical patent/AR080892A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un complejo insoluble en agua que comprende un compuesto estable a la humedad y al calor, amorfo seleccionado a partir del grupo formado por saquinavir y un polímero ionico insoluble en agua que tiene un peso molecular mayor que 80.000 D, una temperatura de transicion vítrea igual o mayor que 50sC, y está seleccionado a partir del grupo formado por poliacrilato, quitosan, polímeros carboxivinílicos, ftalato acetato de polivinilo, ftalato acetato de celulosa, policianoacrilatos, ftalato de hidroxipropilmetilcelulosa, tereftalato acetato de celulosa, succinato acetato de hidroxipropilmetilcelulosa, carboximetilcelulosa e hidroxipropilcelulosa de baja sustitucion, o una mezcla de dos o más de los polímeros ionicos anteriormente descriptos, en donde el compuesto terapéuticamente activo, estable amorfo está incorporado en el complejo compuesto/polímero predominantemente en forma amorfa, de acuerdo a lo determinado por difraccion de rayos X de polvo, y está presente en el complejo insoluble en agua en no menos del 10%, en peso, y el polímero ionico está presente en el complejo en no menos del 20%, en peso. También se dan a conocer: una composicion farmacéutica que comprende dicho complejo, métodos para preparar dicha composicion, método para preparar dicho complejo y un método para estabilizar un compuesto amorfo.
ARP110101253A 1998-09-22 2011-04-13 Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo AR080892A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
AR080892A2 true AR080892A2 (es) 2012-05-16

Family

ID=26798138

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990104725A AR022096A1 (es) 1998-09-22 1999-09-20 Complejos estables de compuestos muy poco solubles
ARP110101253A AR080892A2 (es) 1998-09-22 2011-04-13 Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990104725A AR022096A1 (es) 1998-09-22 1999-09-20 Complejos estables de compuestos muy poco solubles

Country Status (32)

Country Link
US (1) US6350786B1 (es)
EP (1) EP0988863B2 (es)
JP (5) JP2000095708A (es)
KR (1) KR100362019B1 (es)
CN (1) CN1201821C (es)
AR (2) AR022096A1 (es)
AT (1) ATE265232T1 (es)
AU (1) AU770745B2 (es)
BR (1) BR9904283A (es)
CA (1) CA2282906C (es)
CO (1) CO5140077A1 (es)
CZ (1) CZ300215B6 (es)
DE (1) DE69916733T3 (es)
DK (1) DK0988863T4 (es)
ES (1) ES2218918T5 (es)
HR (1) HRP990287B1 (es)
HU (1) HU228341B1 (es)
ID (1) ID24034A (es)
IL (1) IL131957A (es)
MA (1) MA26692A1 (es)
MY (1) MY124377A (es)
NO (1) NO326928B1 (es)
NZ (1) NZ337884A (es)
PE (1) PE20001049A1 (es)
PL (1) PL202757B1 (es)
PT (1) PT988863E (es)
RS (1) RS50193B (es)
RU (1) RU2240827C2 (es)
SG (1) SG97131A1 (es)
SI (1) SI0988863T2 (es)
TR (1) TR199902324A2 (es)
TW (1) TWI234465B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
AR033651A1 (es) * 1999-10-01 2004-01-07 Hoffmann La Roche Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
CA2409003C (en) * 2000-05-16 2010-10-19 Ortho-Mcneil Pharmaceutical, Inc. Process for coating medical devices using super-critical carbon dioxide
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) * 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
CH695418A5 (de) * 2001-05-30 2006-05-15 Csir Verfahren zur Einkapselung eines Wirkstoffs.
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
ATE480226T1 (de) 2001-06-22 2010-09-15 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
WO2004014342A1 (en) 2002-08-12 2004-02-19 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
WO2005046696A1 (ja) 2003-11-14 2005-05-26 Ajinomoto Co., Inc. フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
EP3216449A1 (en) * 2003-11-14 2017-09-13 EA Pharma Co., Ltd. Oral administration preparation of phenylalanine derivatives
US20070191404A1 (en) * 2004-04-01 2007-08-16 Pierre Bartsch Pharmaceutical compositions of pyrimidine-2,4,6-triones
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
JP5209876B2 (ja) * 2004-12-28 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 速崩壊性錠剤及びその製造方法
WO2006073973A2 (en) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006081497A2 (en) * 2005-01-27 2006-08-03 Corium International, Inc. Hydrophilic biocompatible adhesive formulations and uses
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
WO2006123223A1 (en) * 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
CA2660374A1 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
US20080221047A1 (en) 2006-12-27 2008-09-11 Astellas Pharma Inc., Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
JP2011500724A (ja) * 2007-10-19 2011-01-06 パーデュ リサーチ ファンデーション 結晶性化合物の固体製剤
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2581084A4 (en) * 2010-05-31 2014-06-25 Astellas Pharma Inc SOLID DISPERSION COMPRISING A TRIAZOLE COMPOUND
SI2672967T1 (sl) 2011-02-07 2018-12-31 Plexxikon Inc. Spojine in postopki za kinazno modulacijo in indikacije zanjo
KR20140006879A (ko) 2011-02-17 2014-01-16 에프. 호프만-라 로슈 아게 고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
SMT201900179T1 (it) 2011-06-20 2019-05-10 H Lundbeck As 1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
AU2012313971B2 (en) 2011-09-27 2016-09-29 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
LT2765990T (lt) 2011-10-14 2018-01-25 Array Biopharma, Inc. Solidinė dispersija
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
CA2891502A1 (en) 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
CA3053189A1 (en) 2012-12-20 2014-06-26 Kashiv Biosciences, Llc Orally disintegrating tablet formulation for enhanced bioavailability
HK1211217A1 (en) 2013-01-22 2016-05-20 霍夫曼-拉罗奇有限公司 Pharmaceutical composition with improved bioavailability
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
WO2015038376A1 (en) * 2013-09-11 2015-03-19 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
WO2015082562A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
MX2017015322A (es) * 2015-05-29 2018-03-28 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de isotretinoin.
CN108218868B (zh) * 2016-12-13 2019-02-19 南京药捷安康生物科技有限公司 多激酶抑制剂化合物、其晶型及用途
EA201992573A1 (ru) 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. Лечение her2-положительных злокачественных новообразований
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
CA3168667A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
JP7705715B2 (ja) 2020-03-03 2025-07-10 デクセリアルズ株式会社 画像表示装置の製造方法
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
ZA868963B (en) * 1985-11-27 1988-07-27 Syntex Inc Amorphous anthelmintic benzimidazole derivatives
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
JP2528706B2 (ja) † 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) † 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2111065T5 (es) † 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) † 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
EP0784974B1 (en) * 1995-07-26 2003-05-21 Kyowa Hakko Kogyo Co., Ltd. preparation of xanthine derivatives in a solid dispersion
EP0952770A4 (en) † 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
IL126179A (en) 1996-03-12 2003-04-10 Pg Txl Co Lp Pharmaceutical compositions containing anti-tumor drug conjugates
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
EP1064279B1 (en) 1998-03-17 2003-06-25 F.Hoffmann-La Roche Ag Substituted bisindolylmaleimides for the inhibition of cell proliferation

Also Published As

Publication number Publication date
DK0988863T3 (da) 2004-08-30
US6350786B1 (en) 2002-02-26
PE20001049A1 (es) 2000-10-17
RU2240827C2 (ru) 2004-11-27
JP2016196515A (ja) 2016-11-24
PT988863E (pt) 2004-07-30
JP2015187170A (ja) 2015-10-29
HRP990287B1 (en) 2004-12-31
ID24034A (id) 2000-07-06
CZ330499A3 (cs) 2000-04-12
SI0988863T2 (sl) 2009-08-31
MA26692A1 (fr) 2004-12-20
BR9904283A (pt) 2000-09-26
EP0988863B2 (en) 2009-03-18
NZ337884A (en) 2001-02-23
JP2013035875A (ja) 2013-02-21
CA2282906C (en) 2010-07-20
SI0988863T1 (en) 2004-08-31
CO5140077A1 (es) 2002-03-22
RS50193B (sr) 2009-05-06
DE69916733D1 (de) 2004-06-03
DE69916733T3 (de) 2009-09-24
YU47399A (es) 2002-08-12
IL131957A (en) 2005-06-19
TWI234465B (en) 2005-06-21
JP2007224048A (ja) 2007-09-06
DK0988863T4 (da) 2009-06-08
EP0988863A3 (en) 2000-08-09
HUP9903189A3 (en) 2009-07-28
CN1251312A (zh) 2000-04-26
HRP990287A2 (en) 2000-06-30
HUP9903189A2 (hu) 2000-06-28
PL202757B1 (pl) 2009-07-31
CA2282906A1 (en) 2000-03-22
HK1026632A1 (en) 2000-12-22
DE69916733T2 (de) 2005-03-31
ATE265232T1 (de) 2004-05-15
JP2000095708A (ja) 2000-04-04
KR20000023426A (ko) 2000-04-25
TR199902324A3 (tr) 2000-04-21
KR100362019B1 (ko) 2002-11-23
HU9903189D0 (en) 1999-11-29
JP6253135B2 (ja) 2017-12-27
IL131957A0 (en) 2001-03-19
CZ300215B6 (cs) 2009-03-18
TR199902324A2 (xx) 2000-04-21
CN1201821C (zh) 2005-05-18
ES2218918T5 (es) 2009-06-23
HU228341B1 (en) 2013-03-28
NO326928B1 (no) 2009-03-16
AU770745B2 (en) 2004-03-04
NO994583L (no) 2000-03-23
SG97131A1 (en) 2003-07-18
EP0988863A2 (en) 2000-03-29
PL335592A1 (en) 2000-03-27
MY124377A (en) 2006-06-30
JP6534979B2 (ja) 2019-06-26
ES2218918T3 (es) 2004-11-16
AR022096A1 (es) 2002-09-04
EP0988863B1 (en) 2004-04-28
AU4880799A (en) 2000-03-23
NO994583D0 (no) 1999-09-21

Similar Documents

Publication Publication Date Title
AR080892A2 (es) Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo
Wang et al. Progress in research on metal ion crosslinking alginate-based gels
AU2001278471B2 (en) Stable salts of o-acetylsalicyclic with basic amino acids
AR011332A1 (es) Composicion que presenta propiedades de barrera a gases mejorada.
Jesus et al. Highly controlled diffusion drug release from ureasil–poly (ethylene oxide)–Na+–montmorillonite hybrid hydrogel nanocomposites
KR20160028408A (ko) 수용성 히알루론산 겔 및 그의 제조 방법
AU8110498A (en) Pharmaceutical formulations containing voriconazole
ES2383846T3 (es) Composición farmacéutica que comprende S-nitrosoglutatión y un polisacárido
IE921767A1 (en) Methods of using lysophosphatidic acids for regulating skin¹wrinkles
Stoica et al. Evaluation of natural polyphenols entrapped in calcium alginate beads prepared by the ionotropic gelation method
ES8103027A1 (es) Un procedimiento para la preparacion de un polipeptido
DE69907258T2 (de) Verfahren zur herstellung von dinatriumpamidronat
KR20200126078A (ko) 항균 및 항산화 기능의 키토산-만델산 고분자 전해질 복합체 및 그 수용액 조성물
EP0374888A3 (en) Sulfated tannins and theirs salts
CN104606680A (zh) 一种负载药物的γ-聚谷氨酸水凝胶的制备方法
CN103214591B (zh) 一种含末端2,5-脱水塔罗糖或其衍生物的低分子量糖胺聚糖衍生物
ES2238703T3 (es) Alquilaciones selectivas de ciclodextrinas en los niveles de basicidad minima efectiva.
CN115364236A (zh) 一种细胞膜锚定的ros响应壳聚糖凝胶前药体系、制备方法及其应用
CN102552235B (zh) 益母草碱-半胱氨酸缀合物在制备治疗缺血性心肌病药物中的用途
Minzanova et al. Complexes of pectin polysaccharide with acetylsalicylic acid.
EP0338092A1 (en) Anti-hiv agent
CN114853595B (zh) 一种丙戊酸钠、丙戊酸共晶的制备方法及其产品
PT88158B (pt) Processo para a preparacao de um novo derivado de diosmina
BRPI0013686B8 (pt) procedimento para sintetizar uma mistura de oligossacarídeos
Rattie et al. Acetaminophen prodrugs III: Hydrolysis of carbonate and carboxylic acid esters in aqueous buffers

Legal Events

Date Code Title Description
FC Refusal